Teravir
✅ Suppresses HIV replication
✅ Reduces viral load
✅ Boosts immune function
✅ Delays disease progression
✅ Prevents opportunistic infections
Teravir contains Tenofovir.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
Quick Answer — Teravir (Tenofovir Disoproxil 300 mg)
- Active ingredient: tenofovir disoproxil fumarate (TDF) 300 mg, oral tablet, taken once daily with food.
- Primary indication on this listing: chronic hepatitis B virus (HBV) infection in adults — long-term suppression of viral replication. Also used in HIV regimens, but never as HIV monotherapy (resistance risk).
- Mechanism: nucleotide reverse-transcriptase inhibitor (NRTI). Tenofovir-diphosphate competes with natural dATP, gets incorporated into the viral DNA chain, and terminates it.
- HBV efficacy: > 90% achieve undetectable HBV DNA at 5 years; resistance < 1% over 8+ years — the highest barrier to resistance of any oral HBV agent.
- Key safety watch: renal function (eGFR), serum phosphate and bone mineral density — check before treatment, then every 3–6 months. If CrCl drops below 50 mL/min, dose-interval adjustment is required.
- HBV flare warning: stopping tenofovir suddenly in chronic hepatitis B can trigger severe acute hepatic flares — never discontinue without specialist supervision.
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
Why order from MedsBase
Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.
What Is Teravir?
Teravir is an oral tablet containing tenofovir disoproxil fumarate 300 mg (TDF), manufactured by Cipla. Each pack normally contains 30 film-coated tablets.
Tenofovir is a nucleotide reverse-transcriptase inhibitor (NtRTI) used for two distinct chronic viral indications — chronic hepatitis B (HBV) and HIV-1 — both of which use a viral reverse transcriptase to copy their genome. The same molecule is sold under the originator brand Viread (Gilead, approved 2001 for HIV, 2008 for HBV).
What Is Teravir Used For?
- Chronic hepatitis B (CHB) in adults and adolescents ≥ 12 years — first-line oral antiviral for HBeAg-positive and HBeAg-negative chronic infection (EASL, AASLD, APASL, WHO guidelines).
- HIV-1 infection — only as part of a combination regimen, typically with emtricitabine (FTC) or lamivudine (3TC) plus a third agent (integrase inhibitor or NNRTI). Never as HIV monotherapy.
- HIV pre-exposure prophylaxis (PrEP) — usually as the fixed-dose TDF + FTC combination (Truvada / Tenvir-EM); single-agent TDF for PrEP is supported by some guidelines for cisgender heterosexual exposure but is not first-line.
- HIV post-exposure prophylaxis (PEP) — component of the standard 28-day three-drug regimen.
Tenofovir is not active against hepatitis C, herpes simplex, or seasonal flu — it is selective for HIV and HBV reverse transcriptases.
How Does Teravir Work?
Tenofovir disoproxil is a prodrug: after absorption it is hydrolysed to tenofovir, then phosphorylated intracellularly to tenofovir-diphosphate (TFV-DP). TFV-DP is the active metabolite. It is structurally an analogue of deoxyadenosine-5′-triphosphate (dATP).
HBV polymerase and HIV reverse transcriptase mistake TFV-DP for dATP and incorporate it into the growing viral DNA strand. Once incorporated, the missing 3′-hydroxyl group prevents the next nucleotide from being added — the chain terminates. Without complete viral DNA, no new infectious virions assemble.
The intracellular half-life of TFV-DP exceeds 50 hours, which is why once-daily dosing maintains continuous viral suppression and why the drug remains active for several days after a missed dose.
Dosage and How to Take Teravir
| Indication | Standard adult dose | Treatment duration |
|---|---|---|
| Chronic hepatitis B | 300 mg once daily with food | Long-term — usually indefinite. Stopping requires specialist supervision (flare risk). |
| HIV (combination) | 300 mg once daily with food | Lifelong, as part of a multi-drug regimen. |
| PrEP / PEP (combination) | 300 mg + FTC 200 mg once daily | Daily PrEP while at ongoing risk; PEP for 28 days. |
Take with food — raises bioavailability by about 40%. Swallow the tablet whole with water; do not split or crush. If you miss a dose by less than 12 hours, take it as soon as you remember; if more than 12 hours have passed, skip the missed dose and resume the next scheduled one. Do not double up.
Renal-impairment dose adjustment (HBV indication):
- CrCl ≥ 50 mL/min — 300 mg every 24 hours (no change)
- CrCl 30–49 mL/min — 300 mg every 48 hours
- CrCl 10–29 mL/min — 300 mg every 72–96 hours
- Haemodialysis — 300 mg every 7 days, after dialysis on dialysis days
For deteriorating renal function on TDF, switching to tenofovir alafenamide (TAF) — same active drug, lower kidney and bone exposure — is preferred.
Side Effects
Common (≥ 1 in 100 patients): nausea, diarrhoea, headache, fatigue, mild rash, dizziness, hypophosphataemia (often asymptomatic, picked up on bloods).
Uncommon to rare but important:
- Renal toxicity — small, mostly reversible decline in eGFR is common. Proximal tubulopathy and Fanconi syndrome (proteinuria, glycosuria with normal blood glucose, phosphate wasting, bone pain) are uncommon but can be serious. Monitor eGFR, urine protein, serum phosphate at baseline, then every 3–6 months.
- Bone mineral density loss — small reduction in BMD in the first year, then plateaus. Clinically relevant in patients with pre-existing osteoporosis or fragility fracture history.
- Lactic acidosis with severe hepatomegaly — rare class effect of NRTIs. Stop the drug immediately if unexplained progressive abdominal pain, rapid breathing, severe fatigue, or muscle pain develop.
- Severe acute exacerbation of hepatitis B — can occur on stopping TDF, even after years of suppression. Requires monitoring of LFTs and HBV DNA for at least 6 months after discontinuation.
Drug Interactions
Tenofovir has few cytochrome-P450 interactions but several clinically significant pharmacokinetic interactions:
- Didanosine (ddI) — tenofovir raises ddI levels; pancreatitis risk. Combination is generally avoided.
- Atazanavir (unboosted) — tenofovir lowers atazanavir levels. Atazanavir must be ritonavir-boosted when given with TDF.
- Other nephrotoxic drugs — concurrent aminoglycosides, high-dose NSAIDs (especially long-term diclofenac or ibuprofen), cidofovir, foscarnet, IV vancomycin, IV amphotericin B, cisplatin all amplify renal injury risk.
- Adefovir — do not combine with TDF; both are tenofovir-class. Same active metabolite.
- Probenecid, ledipasvir, ranitidine — raise tenofovir exposure; usually still safe but monitor renal function.
Hepatitis C co-infection note: sofosbuvir-based DAA regimens (including Hepcinat LP) are safe with TDF, but ledipasvir raises tenofovir exposure modestly — check eGFR more frequently during the 12-week DAA course.
Who Should Not Take Teravir?
- Severe renal impairment (CrCl < 10 mL/min) without dose adjustment or dialysis access
- Known hypersensitivity to tenofovir disoproxil
- Concurrent treatment with adefovir or didanosine without specialist oversight
- Decompensated cirrhosis — specialist should weigh entecavir vs TDF; both are options.
Pregnancy: tenofovir disoproxil has the strongest pregnancy and breastfeeding safety data of any oral HBV/HIV agent — preferred in pregnancy when treatment is needed (e.g. high-viral-load mother to prevent vertical transmission of HBV from week 28).
Storage
Store at room temperature, below 30°C, in the original bottle with desiccant. Keep out of reach of children. Do not transfer to weekly pill organisers for long periods — the desiccant matters.
Frequently Asked Questions
Is Teravir the same as Viread?
Yes — same molecule, same strength, same indication. Viread is the originator (Gilead). Teravir is a Cipla generic of the same tenofovir disoproxil fumarate 300 mg formulation. Bioequivalence studies are required to register the generic in regulated markets.
Will Teravir cure my hepatitis B?
No. Tenofovir suppresses HBV replication so effectively that viral DNA usually becomes undetectable, ALT normalises, and progression to cirrhosis or hepatocellular carcinoma slows substantially. But the cccDNA reservoir inside infected hepatocytes is not eliminated — stopping the drug allows replication to resume. Functional cure (HBsAg loss) happens in around 1–3% per year of treatment; sterile cure is currently impossible. Treatment is therefore long-term — in many cases lifelong.
Can I use Teravir alone for HIV?
No. Tenofovir monotherapy for established HIV-1 infection causes rapid resistance. HIV requires a minimum of three active drugs from at least two different classes. Teravir is one component of that regimen, never the whole thing.
How long does it take for Teravir to work?
HBV DNA usually starts dropping within 4 weeks. By 6 months, 70–80% achieve undetectable viral load; at 5 years, > 90%. ALT normalisation usually follows DNA suppression by 3–6 months. HBeAg seroconversion (a partial cure marker) happens in around 20–30% of HBeAg-positive patients over 5 years.
Why is renal monitoring so important?
TDF concentrates in proximal renal tubules. The newer alafenamide formulation (TAF) was designed specifically to reduce tubular exposure — same active drug, but plasma levels are 90% lower. Most TDF-related renal decline is small and reversible if caught early; the goal of 3-monthly eGFR and serum phosphate monitoring is to catch the rare progressive cases before structural injury sets in.
Teravir vs TAF (tenofovir alafenamide) — which should I take?
Both deliver tenofovir to hepatocytes (HBV) and to lymphocytes (HIV). TAF achieves higher intracellular levels at much lower plasma exposure, which reduces renal and bone toxicity. TAF is preferred if you have CKD stage 2–3, osteoporosis, or are over 60. TDF (this product) has a 20-year safety database, costs less, and may be slightly preferred in pregnancy where TAF data is still maturing. Talk to your hepatologist or HIV physician about switching if you have any TDF-related toxicity.
Can I drink alcohol on Teravir?
Alcohol does not directly interact with tenofovir, but heavy drinking accelerates liver damage in chronic HBV. Limit alcohol to moderate intake or abstain entirely if you have any fibrosis or cirrhosis.
Can I stop Teravir once my HBV DNA is undetectable?
Generally no. Stopping triggers viral rebound in > 90% of patients within 3 months, and a minority experience severe acute flares with risk of hepatic decompensation. Stopping is only considered after HBsAg loss with anti-HBs seroconversion (functional cure), and even then under specialist supervision with frequent monitoring for 6–12 months.
Does Teravir prevent mother-to-child transmission of HBV?
Yes — in highly viraemic mothers (HBV DNA > 200,000 IU/mL), starting tenofovir disoproxil at week 28 of pregnancy and continuing through the early postpartum period reduces vertical transmission to near zero when combined with active and passive infant immunisation. This is a recognised indication in WHO, EASL, and AASLD guidelines.
Where can I order Teravir?
You can order Teravir directly from MedsBase. We supply genuine Cipla stock with worldwide shipping. We strongly recommend treatment under the supervision of a hepatologist or infectious-diseases specialist for HBV monitoring (LFTs, HBV DNA, fibroscan) and renal monitoring while on therapy.
Disclaimer
The information on this page is for educational purposes and is not a substitute for professional medical advice. Treatment of chronic hepatitis B and HIV requires baseline assessment, ongoing monitoring, and specialist oversight. Do not start, stop, or change tenofovir-based therapy without consulting a qualified clinician.
Patients on Teravir (tenofovir disoproxil fumarate 300 mg) for hepatitis B who also require HIV pre-exposure prophylaxis can consider Tenvir EM (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg), which adds the emtricitabine co-formulation required for approved dual-component PrEP efficacy.
Related Alternatives
Other products in Chronic Conditions that customers also view:
More options in Hepatitis Medication
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 300 mg |
|---|---|
| Quantity | 30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s |
Teravir
Q & A
Teravir
Related products
Reviews
There are no reviews yet